

**RUBRA MEDICAMENTS LIMITED**

**Statement of Standalone Unaudited Financial Results for the Quarter ended June 30, 2017**

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Figures for the previous reporting period
		30-Jun-2017	31-Mar-2017	30-Jun-2016	31-Mar-2017
		Unaudited	Audited	Unaudited	Audited
I	Revenue from Operations	92.30	5.74	7.25	30.62
II	Other Income	6.70	0.25	0.00	0.25
III	<b>Total Income (I + II)</b>	<b>99.00</b>	<b>5.99</b>	<b>7.25</b>	<b>30.87</b>
IV	<b>Expenses:</b>				
	Cost of Materials Consumed	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	86.94	0.00	3.57	12.13
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00
	Employee benefits Expense	0.32	0.70	0.45	2.00
	Finance Costs	0.00	0.01	0.00	0.01
	Depreciation & amortisation expense	0.01	0.01	0.00	0.03
	Other Expenses	6.66	4.42	2.76	13.31
	<b>Total Expenses (IV)</b>	<b>93.93</b>	<b>5.14</b>	<b>6.78</b>	<b>27.48</b>
V	<b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>5.07</b>	<b>0.85</b>	<b>0.47</b>	<b>3.39</b>
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	<b>Profit / (loss) before tax (V-VI)</b>	<b>5.07</b>	<b>0.85</b>	<b>0.47</b>	<b>3.39</b>
VIII	Tax Expense:				
	(1) Current tax	0.00	0.00	0.00	0.00
	(2) Deferred tax	0.00	0.00	0.00	0.00
IX	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>5.07</b>	<b>0.85</b>	<b>0.47</b>	<b>3.39</b>
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00
XII	<b>Profit/(loss) from Discontinuing operations (after tax )(X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit / (Loss) for the period (IX+XII)</b>	<b>5.07</b>	<b>0.85</b>	<b>0.47</b>	<b>3.39</b>
XIV	Other comprehensive income				
	A (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss				
	(ii) Income tax relating to items that will be reclassified to profit or loss				
XV	<b>Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	<b>5.07</b>	<b>0.85</b>	<b>0.47</b>	<b>3.39</b>
	Earnings per equity share (for continuing operation):				
XVI	(1) Basic	0.09	0.02	0.01	0.06
	(2) Diluted	0.09	0.02	0.01	0.06
	Earnings per equity share (for discontinued operation):				
XVII	(1) Basic	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00
	Earnings per equity share (for discontinued & continuing operation):				
XVIII	(1) Basic	0.09	0.02	0.01	0.06
	(2) Diluted	0.09	0.02	0.01	0.06

**Notes:**

1. The above results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.
2. The Segment-wise details are not applicable to the company as company has no segments.
3. The results are Ind-AS compliant however, the previous years figures are not subject to limit review or audit. However, the management has exercised necessary due diligence to ensure that the Financial Results provide a true and fair view of its affairs.
4. The result is provisional and unaudited and subject to change, regrouping and restatement.

For Rubra Medicaments Limited

Date:- August 10, 2017  
Place: Mumbai

  
Abha Kapoor  
Director (Finance) & CFO  
DIN-02799429